Keytruda works by releasing a brake, not by attacking cancer directly. Tumors often hijack a checkpoint pathway called PD-1/PD-L1 to hide from the immune system. Researchers studying tumor biopsies with immunohistochemistry (IHC) found that tumors expressing high PD-L1 were essentially waving a "don't attack me" flag at immune cells. With that realization, blocking that flag became the entire therapeutic strategy to attack the tumor.
Why the Samples Were Essential
- PD-L1 staining on biopsy tissue revealed the immune evasion mechanism itself
- It later became the actual biomarker used to select which patients respond best to checkpoint inhibitors
- This turned "boost the immune system" from a vague idea into a targetable, testable pathway
The Result
Keytruda went on to become one of the best-selling cancer drugs in history, approved across more than a dozen tumor types, but here’s where it gets interesting in 2026…Keytruda and Merck just gained a POWERFUL new partner with Moderna’s personalized mRNA vaccine!
The UPDATE
Merck and Moderna ran a big Phase 3 trial called INTerpath-001 in over 1,100 people with high-risk melanoma (skin cancer) who'd already had surgery to remove their tumors but were at serious risk of it coming back. Researchers found that combining Moderna’s personalized mRNA-based cancer therapy with Keytruda significantly improved the amount of time patients remained cancer-free and reduced the risk of melanoma spreading to other parts of the body, compared with Keytruda alone.
The companies called this the first positive late-stage trial result for an mRNA-based cancer treatment and for an individualized neoantigen therapy. In plain terms: this is the first time a personalized mRNA cancer "vaccine" has proven itself in a large, rigorous trial, and it beat the current gold-standard drug alone. THAT is a big deal!
Earlier (smaller) data had suggested roughly a 49% lower chance of the cancer recurring or the patient dying, an average of five years after taking the drug combination for up to a year, compared to Keytruda by itself, though the full numbers from this specific Phase 3 haven't been published yet, just the "topline" (headline) results. Moderna is set to release those results on October 24, in only a few weeks!
How mRNA Vaccines Work (In General)
Normal vaccines often inject a weakened virus or piece of a virus to cause an immune reaction in your body and send a signal to fight a “foreign invader.” mRNA vaccines take a different route: they inject a set of genetic instructions (messenger RNA) that tell your own cells to temporarily build a specific protein. Your immune system sees that protein, recognizes it as foreign, and mounts a response, including training T-cells and antibodies to recognize and attack anything carrying that same protein in the future. The mRNA itself breaks down naturally within days; it never alters your DNA.
How This Applies to Cancer - The "Personalized" Part
Unlike COVID vaccines, where everyone gets the same shot, this cancer vaccine is custom-built per patient. Tumor sequencing informs a bespoke mRNA encoding up to 34 neoantigens, aiming to amplify tumor-specific T-cell immunity when combined with PD-1 blockade.
In simple terms:
- Doctors sequence the patient's own tumor DNA to find the specific mutations unique to their cancer (called "neoantigens" abnormal proteins not found in healthy cells).
- Moderna manufactures a custom mRNA shot encoding up to 34 of these specific mutant proteins for that individual patient.
- Injected into the patient, their cells produce these abnormal proteins, and the immune system learns to recognize them as a "wanted poster" specifically for that patient's cancer cells, training T-cells to hunt down any remaining cancer cells carrying those exact mutations.
Where Keytruda Fits In (Mechanism of Action)
Keytruda (Pembrolizumab) works completely differently from the mRNA vaccine and that's the whole point of combining them. Cancer cells often exploit a protein called PD-1 found on T-cells, essentially flashing a "don't attack me, I'm normal tissue" signal that disables the immune response. Keytruda is an antibody that blocks PD-1, removing that "off switch" so T-cells stay active and can attack cancer.
The logic of combining the two: the personalized vaccine acts like a training program, teaching the immune system exactly which cancer cells to target, while Keytruda removes the brakes that would otherwise let those trained T-cells get switched off before they can do their job. That's why the combination outperforms Keytruda alone: one builds a cancer-specific army, the other lets that army actually fight.
Why this Matters for the Biosample Story:
This isn't just "sample led to drug discovery" anymore. It's samples becoming a literal ingredient in each individual patient's treatment, in real time. Your tumor biopsy doesn't just diagnose you. Increasingly, it IS the blueprint the drug is built from.
The Takeaway:
From a PD-L1 stain in the 2000s to a personalized mRNA vaccine manufactured from your own tumor's mutations in 2026, the arc of Keytruda's story shows exactly where precision oncology is heading: every patient's biosample becoming their own custom therapy.
Leave a Reply